Nurix Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-11-30 |
2025-11-30 |
2026-11-30 |
2027-11-30 |
2028-11-30 |
2029-11-30 |
| Przychód (średnia) |
54.58 |
91.75 |
66.25 |
84.47 |
167.44 |
335.72 |
| Przychód Δ r/r |
0.00% |
68.11% |
-27.79% |
27.50% |
98.23% |
100.50% |
| Przychód (min) |
41.35 |
77.85 |
40.28 |
84.47 |
115.99 |
232.55 |
| Przychód (max) |
64.72 |
113.24 |
153.34 |
84.47 |
270.54 |
542.43 |
| EBITDA (średnia) |
-54.58 |
-91.75 |
-66.25 |
-84.47 |
-167.44 |
-335.72 |
| EBIT (średnia) |
-54.58 |
-91.75 |
-66.25 |
-84.47 |
-167.44 |
-335.72 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-193.57 |
-192.67 |
-332.49 |
-212.21 |
-177.58 |
-92.24 |
| Zysk netto % |
-354.67% |
-209.99% |
-501.87% |
-251.23% |
-106.05% |
-27.48% |
| EPS (średnia) |
-2.81 |
-2.87 |
-3.55 |
-3.41 |
-2.65 |
-1.37 |
| Liczba analityków (Przychody) |
13 |
11 |
13 |
11 |
4 |
5 |
| Liczba analityków (EPS) |
12 |
12 |
12 |
9 |
8 |
3 |
| symbol |
NRIX |
NRIX |
NRIX |
NRIX |
NRIX |
NRIX |